Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Pre-Tax Margin
Income before tax as a percentage of revenue.
Alumis Inc. Common StockNASDAQ: ALMS
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin narrows to -8662.9%
Pre-tax margin was -8662.9% in Q2 FY2026, down 10566.9 pp from a year earlier. On a trailing-twelve-month basis it was -5957.2%, down 4780.0 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1047.3%
- Year-over-year change
- —
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1047.3% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
Pre-Tax Margin vs competitors
How ALMS compares with its peers on the latest reported figures
- ALMS's LTM Jun 2026 pre-tax margin of -5957.2% is the 4th highest of the 6 companies compared; the peer median is -832.6%.
- Its year-over-year change of -4780.0 pp is the 4th highest of 6, against a peer median of -100.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 40.7% | +21.9 pp | +90.1 pp | |
| LTM Mar 2026 | -11.5% | +114.2 pp | +1245.5 pp | |
| LTM Mar 2026 | -832.6% | -100.2 pp | -537.5 pp | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -5957.2% | -4780.0 pp | — |
| LTM Mar 2026 | -143340.7% | -159922.8 pp | -132132.1 pp | |
| LTM Mar 2026 | -145945.5% | -112373.1 pp | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ALMS) | -832.6% | -100.2 pp | -223.7 pp | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | 250K | 0 | 3.15M | 3.5M |
| Gross Profit | (250K) | 0 | (3.15M) | 20.55M |
| Gross Margin | — | — | — | 85.5% |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 447.76M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| EBITDA | (111.68M) | (153.71M) | (291.08M) | (248.39M) |
| EBITDA Margin | — | — | — | -1032.8% |
| Operating Income | (113.85M) | (158.17M) | (300.75M) | (427.2M) |
| Operating Margin | — | — | — | -1776.3% |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | 3.18M | 6.52M | 175.32M |
| Income Before Tax | (111.93M) | (154.99M) | (294.23M) | (251.89M) |
| Pre-Tax Margin | — | — | — | -1047.3% |
| Income Tax Expense | 0 | 0 | 0 | (8.56M) |
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Net Margin | — | — | — | -1011.7% |
| EPS (Basic) | (14.93) | (2.99) | (10.38) | (2.32) |
| EPS (Diluted) | (14.93) | (2.99) | (10.38) | (2.32) |
| Weighted Avg Shares | 7.5M | 51.84M | 28.34M | 850.3M |
| Weighted Avg Shares (Diluted) | 7.5M | 51.84M | 28.34M | 850.3M |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.